Overview of Chericof

Quick Facts

Property	Description
Active ingredient	Dextromethorphan Hydrobromide (DMX)
Form	Oral solution (Syrup)
Pharmacological class	Antitussive agent (Cough suppressant)
Common use	Symptomatic relief of non-productive cough
Origin	Synthetic opioid derivative (non-narcotic)

The Antitussive Agent Dextromethorphan Hydrobromide

Chericof is a medicinal preparation centered on the active ingredient Dextromethorphan Hydrobromide, which is scientifically classified within the pharmacological class of antitussive agents, or cough suppressants. The function of an antitussive agent is to act directly on the central nervous system to reduce the urge to cough. The Dextromethorphan Hydrobromide compound is clinically recognized for its role in reducing the severity and frequency of coughing. As such, the medicine’s primary function is to suppress the urge to cough.

Composition and Central Action

The preparation is a single-ingredient product (monotherapy), containing only the Dextromethorphan Hydrobromide substance dissolved in an aqueous solution base, typically provided as a flavored syrup for oral administration. Although Dextromethorphan is chemically a synthetic opioid derivative, it functions as a non-narcotic agent at therapeutic antitussive levels. This unique feature means its effect is selectively focused on the cough reflex mechanism rather than systemic pain relief or sedation.

General Purpose: Controlling Non-Productive Cough

The general purpose of this medicine is to control the persistent, involuntary cough reflex often seen during minor respiratory irritations. The Dextromethorphan Hydrobromide compound achieves this by acting directly on the cough center located in the medulla oblongata of the brain, a centrally-acting agent that functions by elevating the threshold for coughing. The benefit of this mechanism is the reliable reduction of intensity and frequency of a non-productive cough, which is typically dry and irritating and serves no necessary physiological function in clearing the airways.

Regulatory References

Dextromethorphan - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Chericof?

Possible side effects and safety information

The safety profile of Dextromethorphan Hydrobromide is based strictly on classifications found in government regulatory documents.

Adverse Reactions by System and Frequency

Adverse reactions are formally grouped by the body system affected and their likelihood of occurrence at therapeutic doses. In official labeling, side effects are generally classified as uncommon.

System-Organ Class (SOC)	Examples of Officially Documented Adverse Reactions (Uncommon)
Nervous System Disorders	Drowsiness (somnolence), dizziness, mild mental confusion.
Gastrointestinal Disorders	Nausea, vomiting, and abdominal discomfort or general gastrointestinal upset.
Immune System Disorders	Hypersensitivity reactions, including rash and urticaria (hives).

Serious Safety Constraints

The regulatory profile identifies specific high-level risks and constraints that are not common side effects but require attention.

Regulatory documents emphasize the risk of Serotonin Syndrome when Dextromethorphan is used alongside certain other medicines, such as Monoamine Oxidase Inhibitors (MAOIs). This is considered a potentially life-threatening reaction. Symptoms related to acute toxicity or overdose, including respiratory depression and severe confusion, are also documented safety concerns. The label also notes that Dextromethorphan can cause impairment of cognitive function and alertness.

Population and Exposure Considerations

Caution is officially advised for use in individuals with hepatic impairment due to the drug's metabolism. Furthermore, the potential for drug dependence is noted in official documents concerning prolonged use or use exceeding therapeutic levels, thereby establishing a duration-related safety pattern.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the active ingredient, Dextromethorphan Hydrobromide, may present with a specific profile of documented clinical manifestations. The official regulatory documents note that overdose can result in Central Nervous System (CNS) effects, including somnolence (drowsiness), ataxia (unsteady walking), confusion, agitation, and dizziness. Gastrointestinal effects such as nausea and vomiting are also commonly documented.

Severe and Life-Threatening Outcomes

In severe cases, the toxicity can escalate to life-threatening outcomes, including respiratory depression (slowed or shallow breathing), generalized seizures (convulsions), and coma. Overexposure can also lead to systemic signs such as hyperpyrexia (high fever) and tachycardia (rapid heart rate). A serious, documented risk, particularly when Dextromethorphan is taken alongside other serotonin-affecting agents, is the development of serotonin syndrome.

Mandated Emergency Action

Official regulatory guidance requires that immediate medical attention must be sought for any suspected overdose. You must call your local emergency number or contact a poison control center immediately. Management is based on providing symptomatic and supportive treatment. Healthcare professionals may consider procedures like the administration of activated charcoal and the use of Naloxone to manage severe CNS and respiratory depression, as noted in authoritative clinical guidance. Young children are a population at specific risk for severe respiratory complications from overexposure.

Therapeutic Uses of Chericof

What Chericof Treats: Main Uses and Benefits

The medication is commonly used to provide symptomatic relief by addressing specific distressing manifestations associated with upper respiratory issues. As an antitussive, the medication is used to temporarily relieve cough caused by the common cold, flu, or other minor irritations.

Targeting the Irritating, Non-Productive Cough

Chericof is applied in situations involving certain distressing symptoms, primarily targeting the dry, tickly, and non-productive cough that lacks mucus production. The primary way this medication works is by suppressing the involuntary urge to cough, which contributes to easing the overall symptom burden. This supportive relief is relevant for managing challenging symptoms caused by viral irritation during acute episodes of upper respiratory tract infections.

Improving Comfort and Rest

The medication is commonly used to help with cough associated with the common cold, influenza, and minor bronchial or throat irritation. Relevant when symptoms become temporarily overwhelming, it supports patients during periods of heightened discomfort. By decreasing the frequency and intensity of persistent coughing, it provides support that contributes to improved comfort during periods of heightened symptoms and assists with maintaining a sense of stability, especially when symptoms interfere with rest.

Quick Fact: Relief for Non-Productive Cough The medication is relevant for managing the dry and persistent cough that lacks mucus production, and may assist with decreasing both the frequency and intensity of coughing episodes.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Must Not Use Chericof (Contraindications)

Chericof (Dextromethorphan Hydrobromide) is strictly contraindicated for certain populations based on serious health risks defined by regulatory agencies. This medicine must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), nor should it be taken within 14 days of discontinuing MAOI therapy. It is also prohibited for any individual with a known hypersensitivity or allergy to Dextromethorphan or any component in the formulation. Many international regulatory guidelines mandate that the medicine is contraindicated in children under 12 years of age.

Populations Requiring Caution

Official labeling defines several conditions that necessitate caution or restriction. Use is not recommended for a cough that is chronic (e.g., associated with smoking or asthma) or for coughs accompanied by excessive phlegm. Caution is required for patients with hepatic impairment or severe renal impairment due to potential changes in drug clearance. For pregnant and breastfeeding women, the medicine is generally not recommended unless a physician deems its use essential, reflecting a lack of established safety data. Over-the-counter use is typically not authorized for children younger than four years of age.

What should I know about interactions with other medicines?

The official interaction profile for Dextromethorphan Hydrobromide is defined by regulatory constraints related to its metabolism and central nervous system (CNS) activity. The most significant restriction is the contraindication with Monoamine Oxidase Inhibitors (MAOIs), which include certain medicines used for Parkinson's disease or depression. Co-administration is prohibited due to the risk of a severe, life-threatening Serotonin Syndrome, a documented pharmacodynamic interaction. A mandatory 14-day separation window must be observed: Dextromethorphan cannot be used within 14 days of discontinuing an MAOI, and vice versa.

The drug’s primary metabolic pathway involves the Cytochrome P450 2D6 (CYP2D6) enzyme. Co-administration with strong or moderate CYP2D6 inhibitors, such as certain antidepressants, creates a pharmacokinetic interaction that reduces the clearance of Dextromethorphan. This results in an officially documented increase in its plasma concentrations and systemic exposure.

Additional pharmacodynamic interactions exist with other serotonergic agents and CNS depressants. Combining Dextromethorphan with agents like SSRIs or SNRIs increases the documented risk of Serotonin Syndrome. Co-use with other CNS depressants, including alcohol (ethanol), increases the potential for additive CNS depressant effects. Individuals identified as Poor CYP2D6 Metabolizers are noted in labeling to have a higher risk of drug accumulation and exposure-related consequences. The official profile also includes the restriction to avoid grapefruit or grapefruit juice, as these inhibit the drug's metabolism.

Mechanism of Action

Central Cough Reflex Suppression

This domain involves the action of the antitussive component, Dextromethorphan, which engages receptors in the cough center of the brainstem (specifically within the nucleus tractus solitarius). It initiates a signaling sequence that modifies the early molecular steps of the cough reflex arc, resulting in a predictable physiological adjustment that decreases the afferent signaling response in the brainstem.

Peripheral Vasoconstriction and Modulation

This mechanism is mediated by Phenylephrine, an alpha1-adrenergic receptor agonist. Its activity within the vascular system (specifically the small vessels of the nasal mucosa) modulates key pathways associated with capillary permeability. This engagement leads to the constriction of blood vessels, which attenuates the cascade initiated by excessive mediator activity and re-establishes normal vascular tone within the nasal passages, resulting in the physiological adjustment of reduced capillary permeability and plasma filtration in the nasal mucosa.

Histamine Receptor Modulation

The third domain is driven by the antihistamine, Chlorpheniramine, which acts as an antagonist at the H1 histamine receptor. This engagement blocks the effects of histamine—a key mediator involved in inflammatory cascades—in systems where these transmitters dominate. This suppression of histamine signaling modulates the downstream effects on capillary beds and exocrine glands, affecting the physiological response pattern driven by histamine release.

Dosage and Administration Information

How Chericof is Used: Official Administration Guidelines

Chericof (Dextromethorphan Hydrobromide Oral Solution) is administered according to specific, standardized protocols. These guidelines dictate the correct route, dose, frequency, and duration of use.

Dosing and Frequency

The medication is for oral use only. The adult dosing schedule is based on the specific strength taken, with a strict limit on the total amount administered within a 24-hour period. Doses may be taken with or without food.

Administration Detail	Official Guideline
Standard Adult Dose	10 mg to 20 mg of Dextromethorphan.
Frequency (10-20 mg)	Every 4 hours.
Alternative Adult Dose	30 mg of Dextromethorphan.
Frequency (30 mg)	Every 6 to 8 hours.
Maximum Daily Dose	120 mg in a 24-hour period.

Administration Procedure and Course Duration

Correct administration requires precision to avoid accidental overuse. The dose is to be measured using a calibrated dosing device typically supplied with the product, rather than a household spoon. The medication is intended for short-term use only.

Use should generally not exceed 7 days unless advised otherwise. Dosage instructions for older adults (over 65) are typically the same as for adults, though caution is advised for patients with hepatic impairment due to the drug’s metabolism.

Recent Clinical Evidence

Evidence Summary

Clinical research on combination products containing Dextromethorphan (a cough suppressant), Chlorpheniramine (an antihistamine), and Phenylephrine (a nasal decongestant) has examined their role in managing non-productive cough and symptoms related to the common cold and allergic rhinitis. Studies investigate whether the co-administration of these agents is associated with changes in symptom severity, frequency, and duration.

Overview of Key Clinical Trials

Dextromethorphan/Chlorpheniramine Combination

One post-marketing surveillance study investigated the effects of a fixed-dose combination of Dextromethorphan and Chlorpheniramine in patients with unproductive cough due to allergic rhinitis. The study focused on symptom reduction over a short period. Efficacy findings included a reported reduction in the mean Cough Severity Score (CSS) from a baseline of 6.157 to 1.034 by Day 5 of treatment. Trial participants most commonly reported adverse events of mild intensity.

Dextromethorphan Monotherapy Studies

Research has explored the effects of Dextromethorphan alone on acute cough. While some controlled trials reported statistically significant reductions in cough frequency and sound pressure level within treatment groups, the differences observed between the Dextromethorphan group and the placebo group were often small or statistically non-significant in certain measured outcomes. Findings for the use of Dextromethorphan in the pediatric population remain mixed, with limited high-quality evidence to support its effectiveness for acute cough.

Safety Considerations

Both Chlorpheniramine, a first-generation antihistamine, and Dextromethorphan have been studied for safety. Specific warnings relate to the potential for central nervous system (CNS) effects, such as drowsiness and impaired mental alertness, particularly due to the Chlorpheniramine component. The risk of these CNS effects may be increased when the combination is used alongside alcohol or other agents that affect the central nervous system.

Key Studies & References

National Institute for Health and Care Excellence (NICE) Clinical Guideline: Cough (acute): antimicrobial prescribing

Frequently Asked Questions (FAQ)

Common questions about Chericof (FAQ)

Q: Is Chericof considered a prescription or over-the-counter medicine?

A: Chericof is classified by regulatory authorities as an over-the-counter (OTC) medicine. This means that the medicine can be purchased without requiring a doctor's prescription, based on the official determination of its safety profile for general use.

Q: How quickly do people typically notice an effect from Chericof?

A: The onset of the drug's action is typically described as occurring within 15 to 30 minutes after taking the dose, according to regulatory pharmacokinetics data. This information is based on the drug's intended action time as defined by official sources.

Q: Is Chericof the same as other medicines with similar names?

A: Official product information states that Chericof is a single-ingredient product, containing only Dextromethorphan Hydrobromide. Other cough or cold medicines with similar names may contain different active ingredients or a combination of substances.

Q: What is the difference between Chericof and a standard cough syrup?

A: Chericof is specifically described in official sources as containing the antitussive agent Dextromethorphan. An antitussive agent is used to suppress the urge to cough by acting on the central nervous system.

Q: What should I know about taking Chericof with everyday pain relievers?

A: Regulatory warnings for interactions primarily focus on specific classes of medicines, such as MAOIs, serotonergic agents, and CNS depressants. The official product labeling does not typically list specific warnings or restrictions for co-administration with common, non-serotonergic, over-the-counter pain relievers.

Q: Why do some people say Chericof did not work for their symptoms?

A: Studies that have examined Dextromethorphan monotherapy sometimes report variability in efficacy. Clinical trial evidence has occasionally shown that the differences in measured outcomes between the drug group and the placebo group were small or statistically non-significant in certain measured outcomes.

Q: Is there a certain time of day that Chericof is usually taken?

A: Official administration guidelines focus on the required time intervals between doses, such as every 4 or every 6 to 8 hours. The regulatory documents do not mandate a particular time of day for beginning treatment. The medicine is intended to be taken as symptoms occur, following the recommended frequency.

Q: What happens if a dose of Chericof is missed?

A: Standard patient information, derived from regulatory labeling, describes that a missed dose may be taken as soon as remembered, unless it is almost time for the next scheduled administration. When this happens, the missed dose is typically skipped to prevent overuse.

Q: How long does the effect of Chericof generally last?

A: The duration of the drug's intended effect aligns with the official recommended dosing intervals. These intervals are determined by regulators and are set for either every 4 hours or every 6 to 8 hours, depending on the administered strength.

Q: Is it okay to take Chericof if I have diabetes?

A: The official label includes a complete inactive ingredients list that specifies the type of sweetener used in the oral solution (syrup). Warnings related to the inactive ingredients for specific patient populations, such as those with diabetes, are typically noted in the labeling.

Q: Does Chericof interact with common herbal supplements like St. John's Wort?

A: Regulatory documents warn against co-administration with all serotonergic agents, due to the documented risk of increased serotonin activity. This category of medicines includes some herbal supplements, such as St. John’s Wort.

Q: Do people often use Chericof for night-time symptoms?

A: Regulatory labels allow for a flexible dosing frequency, with intervals up to every 8 hours, which permits use for night-time symptoms. Furthermore, official safety constraints note the potential for drowsiness as a side effect.

Q: Does taking Chericof affect the results of any common medical tests?

A: Official labeling includes a warning that Dextromethorphan can cause interference with certain laboratory procedures. Specifically, it can cause false positive results for certain substances in specific urine drug screening tests.

Q: If I am taking vitamins, is it still appropriate to use Chericof?

A: Official interaction profiles list specific classes of medicines, alcohol, and grapefruit as having documented pharmacological interactions with Chericof. Vitamins are not typically listed among these restricted substances in regulatory warnings.

Q: Can Chericof be used for flu symptoms?

A: The drug is officially indicated for the symptomatic relief of non-productive cough. This type of cough may be associated with various minor respiratory irritations, including those seen during a common cold or flu-like illness.

Q: What color is the Chericof medicine or tablet usually?

A: Official product descriptions specify the physical characteristics of the medicine on the labeling. Chericof (oral solution) is described as a colored liquid, and the precise color is noted in the description section of the regulatory documents.

Q: Do studies report any long-term effects from using Chericof?

A: Official labeling designates Chericof for short-term use only, generally recommending use not to exceed 7 days. Regulatory documents also note the potential for drug dependence in cases of prolonged use or use exceeding therapeutic levels.

Q: Does Chericof contain common allergens like gluten or lactose?

A: The inactive ingredient list is officially defined on the product label to ensure patient safety regarding all components. Information about common allergens, such as gluten or lactose, is included in the full list of ingredients as required by regulatory agencies.

Q: Can I take Chericof if I am allergic to similar cold medicines?

A: Regulatory documents state that the medicine is contraindicated only for individuals with a known hypersensitivity or allergy to the active ingredient, Dextromethorphan, or any other component in the Chericof formulation. The official product labeling does not typically address allergies to other ingredients that might be found in different, similar cold products.

Q: Are there different strengths or formulations of Chericof?

A: Official product information confirms that Chericof is available in different strengths (concentrations) of the active ingredient. This is described to accommodate the different dosage amounts authorized for adults and older adolescents. These details are listed in the regulatory documents defining the drug's supply.

Q: What is the difference between the adult and pediatric versions of Chericof?

A: Official regulatory guidelines define differences primarily through age restrictions and maximum dosage. The medicine is generally contraindicated or not authorized for use in children under 12 years of age. Dosing is strictly defined for adult use, reflecting the specific safety profile in different age groups.

How should Chericof be stored and disposed of?

How to Store and Dispose of Chericof?

Official regulatory guidance specifies strict requirements for the storage and disposal of this Dextromethorphan Hydrobromide oral solution.

Storage Requirements

The medicine must be kept at a controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), and refrigeration is prohibited.

It is mandatory to store the syrup in its original container with the cap tightly closed to protect it from excess heat and moisture. To ensure safety, the product must be placed in a location that is securely out of the sight and reach of children.

Disposal Instructions

When discarding unused or expired product, the preferred method is utilizing a drug take-back program or an authorized collection site. If a take-back option is unavailable, the syrup must be mixed with an undesirable substance (such as dirt) and sealed in a container before being placed in the household trash. Do not flush the medicine down a toilet or pour it down a sink to avoid environmental release.

Chericof